Table 2.
Comparison of efficacy between novel anti-HER2 ADCs and T-DM1.
| Type of response no. (%) | Novel anti-HER2 ADCs (n = 73) | T-DM1 (n = 71) | P |
|---|---|---|---|
| CR | 0 | 0 | |
| PR | 40 (54.8) | 16 (22.5) | |
| SD | 29 (39.7) | 49 (69.0) | |
| SD ≥ 6 | 8 (11.0) | 18 (25.4) | |
| PD | 4 (5.5) | 6 (8.5) | |
| ORR | 40 (54.8) | 16 (22.5) | <.001 |
| CBR | 48 (65.8) | 34 (47.9) | .03 |
Abbreviations: HER2: human epidermal growth factor receptor 2; ADCs: antibody-drug conjugates; T-DM1: trastuzumab emtansine; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; ORR: objective response rate; CBR: clinical benefit rate.